Innovations & Interventions: ACC.19 Will Explore the ‘World of Cardiology’

acc.png

Source

© ACC/Todd Buchanan 2018

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

FDA: Higher doses of tofacitinib tied to increased risks of death, pulmonary embolism

The FDA issued a safety alert Feb. 25 warning that a 10 mg, twice-daily dose of tofacitinib—sold under the brand names Xeljanz and Xeljanz XR—has been linked to an increased risk of pulmonary embolism and death in patients with rheumatoid arthritis. That dose is only approved for patients with ulcerative colitis, the agency said.